New device aims to curb opioid withdrawal without drugs
NCT ID NCT04916600
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a device called NET that uses mild electrical stimulation to reduce opioid withdrawal symptoms. It involves 108 adults who want to stop using opioids without taking other medications. Participants are randomly assigned to get real or sham device treatment, and researchers measure withdrawal severity and abstinence over 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- NET device (a non-invasive electrical stimulation device)
- What this could lead to
- If it works, this could offer a drug-free way to manage opioid withdrawal symptoms, helping people achieve abstinence without medication.
- What could go wrong
- This is an early-stage study with only 108 participants, and it compares the device to a sham (fake) device. The device may not work better than placebo, and long-term effectiveness is unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
108 people
The number who actually took part.
- Started
-
Nov 2021
- Expected to finish
-
Dec 2025
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Provision of signed and dated informed consent form. 2. Stated willingness to comply with all study procedures and availability for the duration of the study (including inpatient stay and participation in video assessments and remote drug screens for the duration of the 12-week outpatient study period). 3. Stated desire to be opioid abstinent without medications for treating opioid use disorder. 4. Male or female, aged 18-65 years. 5. In good general health as evidenced by medical history. 6. Meet Diagnostic and Statistical Manual (DSM)-5 criteria for opioid use disorder (any severity level) alone or comorbid with stable medical diseases (except for certain medications below). 7. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method for the duration of the study. 8. Initiating opioid discontinuation at Isaiah House. 9. Clinical Opiate Withdrawal Scale (COWS) total score is 13 or greater. Exclusion Criteria: 1. Acute/unstable illness: conditions making it unsafe to participate. 2. Chronic illnesses: primarily seizures and dementing illnesses, including medications for these neurological conditions. 3. Current serious psychiatric disease: psychosis, bipolar disorder. 4. Requiring detoxification from alcohol or benzodiazepines. 5. Current use of anxiolytics, hypnotics (prescription and over the counter), antidepressants, anticonvulsants, sedating histamine-1 receptor subtype antihistamines (non-sedating second generation histamine-4 receptor subtype antihistamines are allowed), prescription and over the counter stimulants. 6. Current diagnosis other than opioid use disorder requiring chronic opioid treatment. 7. Presence of a cardiac pacemaker. 8. Pregnancy or lactation. Females who do not agree to sexual abstinence or are heterosexually active and not using (self-report) medically approved birth control measures (sterilization, tubal ligation, oral/depot contraceptives, abstinence, intrauterine device, barrier method such as condom/foam, or a cervical cap combined with a spermicide), are not eligible. 9. Receiving extended-release buprenorphine (Sublocade) within 300 days of enrollment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Opioid-use disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Isaiah House Treatment Center
Willisburg, Kentucky, 40078, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can exercise boost brain and body health during opioid treatment?
- Can a new drug calm the storm of opioid withdrawal?
- Can coaching turn rural clinics into One-Stop shops for addiction and infectious disease care?
- Can a Phone-Based platform keep people in opioid treatment?
- A safety net after jail: can checkups keep opioid treatment on track?
- Can AI and peer support close the opioid treatment gap?